HB1416

Oklahoma HB1416 mandates that insurers ensure non-opioid drugs approved by the FDA are not disadvantaged in coverage compared to opioids.

Oklahoma HB1416 establishes that insurers must ensure non-opioid drugs approved by the United States Food and Drug Administration for pain treatment are not less favorable in coverage compared to opioid drugs. The law defines terms such as "group insurance plan," "health care prescriber," and "insurer." It allows insurers to prefer certain drugs over others but requires non-opioid drugs to be considered equally once FDA-approved. This applies to drugs covered under group insurance plans and contracts with pharmacy benefits managers. The law takes effect November 1, 2025.